Through the looking glass: Current and future perspectives on the role of hormonal interplay in glucose homeostasis

Diabetes Educator

Volumn 33, Issue 2, 2007, Pages

  Kruger, Davida F ^a   Aronoff, Stephen L ^b,c   Edelman, Steven V ^d,e  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Endocrine Associates   (United States)

^d Taking Control of Your Diabetes   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; ANTIDIABETIC AGENT; GLUCOSE; HORMONE; PRAMLINTIDE;

BLOOD; CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; REVIEW;

AMYLOID; BLOOD GLUCOSE; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCOSE; HORMONES; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 33847632603     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721707299766     Document Type: Review

References (28)

1. AACE Diabetes Medical Guidelines Task Force. AACE diabetes guidelines. Endocr Pract. 2002 ; 8 (suppl 1). 41-65.
2. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003 ; 26 (suppl 1). S33 - S50.
3. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004 ; 27: 17-20.
4. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004 ; 291: 335-342.
5. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003 ; 26: 881-885.
6. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther. 2002 ; 4: 175-189.
7. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352: 837-853.
8. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA. 1998 ; 280: 140-146.
9. Unger RH. Glucagon physiology and pathophysiology. N Engl J Med. 1971 ; 285: 443-449.
10. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med. 1970 ; 283: 109-115.
11. Wahren J, Felig P, Hagenfeldt L. Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. J Clin Invest. 1976 ; 57: 987-999.
12. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology. 1995 ; 109: 755-765.
13. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia. 1993 ; 36: 857-862.
14. Phillips WT, Schwartz JG, McMahan CA. Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. J Nucl Med. 1992 ; 33: 1496-1500.
15. Nowak TV, Johnson CP, Wood CM, et al. Evidence for accelerated gastric emptying in asymptomatic patients with insulin-dependent diabetes mellitus. Gastroenterology. 1990 ; 98: A378 - A378.
16. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ. 1999 ; 25: 389-397.
17. Symlin® (pramlintide acetate) injection [prescribing information]. San Diego, Calif: Amylin Pharmaceuticals Inc; 2005. Available at: http://symlin.com/pdf/SYMLIN-pi-combined.pdf. Accessed October 18, 2006.
18. Kong M-F, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia. 1998 ; 41: 577-583.
19. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyper-glucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002 ; 34: 504-508.
20. Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002 ; 51: 636-641.
21. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005 ; 48: 838-848.
22. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003 ; 26: 784-790.
23. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002 ; 4: 51-61.
24. Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev. 2004 ; 20: 55-60.
25. Weyer C, Gottlieb A, Kim DD, et al. Pramlintide reduces post-prandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care. 2003 ; 26: 3074-3079.
26. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002 ; 25: 724-730.
27. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004 ; 21: 1204-1212.
28. Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 ; 29: 2189-2195.